Exam II Flashcards

(175 cards)

1
Q

Hormones of the anterior pituitary

A

Adrenocortocptropic hormone (ACTH)

Melanocyte-stimulating hormone (MSH)

Thyroid-stimulating hormone (TSH)

Follicle-stimulating hormone (FSH)

Luteinizing hormone (LH)

Growth hormone (GH)

Prolactin Beta-Lipotropin (fat catabolism)

Beta-endorphins (pain perception)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Hormones of the posterior pituitary

A

Synthesized in the nuclei of the hypothalamus

Stored and secreted by the posterior pituitary

  • Antidiuretic hormone (ADH, arginine vasopressin)
  • Oxytocin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ADH

A

Antidiuretic hormone (ADH, arginine vasopressin)

Controls plasma osmolality

Causes water reabsorption into the blood

Is released when plasma osmolality is increased or intravascular volume is decreased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hormones of the Hypothalamus

A

Prolactin-inhibiting factor (PIF)

Thyrotropin-releasing hormone (TRH)

Gonadotropin-releasing hormone (GnRH)

Somatostatin

Growth hormone-releasing factor (GRF)

Corticotropin-releasing hormone (CRH)

Substance P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Other name for Anterior pituitary

A

adenohypophysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Other name for Posterior pituitary

A

neurohypophysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Examples of Steroids (Lipid-Soluble) Hormones

A

Androgens, estrogens, progestins, glucocorticoids, mineralocorticoids, vitamin D, retinoid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What do steroids activate?

A

Ribonucleic acid (RNA) polymerase

Deoxyribonucleic acid (DNA) transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

General characteristics of hormones

A

Specific rates and rhythms of secretion

Operate within feedback systems

Affect only cells with appropriate receptors

Are inactivated by the liver or directly excreted by the kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is up-regulation of hormones?

A

Low concentrations of hormones increase the number of receptors per cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is down-regulation of hormones?

A

High concentrations of hormones decrease the number of receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

The five steps of bone repair

A

Hematoma formation

Procallus formation

Callus formation

Replacement

Remodeling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Synarthrosis

A

Immovable

Typically fibrous Joints

 Examples: Sutures, syndesmoses, and gomphoses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Amphiarthrosis

A

Slight movement

Typically cartilaginous joints
 Symphysis
 Synchondrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Symphysis

A

Bones are united by a pad or disk of fibrocartilage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Synchondrosis

A

Bones are united by hyaline cartilage (costal cartilage)

• Examples: Joints between the ribs and the sternum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Diarthrosis

A

Move freely

Typically synovial joints

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Five classifications of bone fractures

A
  • Complete
  • Incomplete
  • Comminuted
  • Linear
  • Oblique
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is a sTrain?

A

Injury to a Tendon

o Tear or injury to a tendon (fibrous connective tissue that attaches skeletal muscle to bone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is a sPrain?

A

Injury to a ligament

o Tear or injury to a ligament (fibrous connective tissue that connects bones)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is rhabdomyolysis?

A

Breakdown of muscle

 Protein pigment myoglobin enters extracellular space, then to the blood stream and eventually to the kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Crush syndrome

A

Rhabdomyolysis

o Can cause kidneys to shut down

o Can be life threatening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How do you treat Rhabdomyolysis?

A
  • Rapid intravenous hydration

- If hyperkalemic, may require hemodialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Treatment of RA

A
  • Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX, first line), azathioprine, sulfasalazine, hydroxychloroquine, leflunomide, and cyclosporine<
  • Biological DMARDs (bDMARDs): Medications affect specific processes in the development of RA, such as TNF
  • NSAIDs, glucocorticoids, intraarticular steroid injections
  • Physical and occupational therapy with therapeutic exercise and use of assistive devices
  • Surgery: Synovectomy or joint replacement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Osteomyelitis
- Is usually caused by a Staphylococcus aureus infection - Is often outside the body (exogenous); can be from a bloodborne (endogenous) infection  Infection spreads under the periosteum and along the bone shaft or into the bone marrow  In adults: Affects the cortex  Sequestra: Sections of dead bone from periosteal separation  Involucrum: Periosteal new bone
26
Clinical manifestations of Osteomyelitis
Acute and chronic inflammation, fever, pain, necrotic bone
27
Treatment of Osteomyelitis
Antibiotics, debridement, surgery, hyperbaric oxygen therapy
28
Primary V Secondary lesions
Primary develop directly from disease process and secondary from primary lesions or from patient behavior such as picking/scratching
29
Seborrheic Keratosis
Benign tumor of the skin o Proliferation of cutaneous basal cells that produce smooth or warty elevated lesions o Treatment: Cryotherapy with liquid nitrogen or electrocautery
30
Keratoacanthoma
Benign tumor of the skin o Tumor of squamous cell differentiation arising from hair follicles o Treatment: Curettage or excision; intralesional fluorouracil (5-FU), bleomycin, interferon or methotrexate
31
Actinic Keratosis
Benign tumor of the skin o Premalignant lesion composed of aberrant proliferations of epidermal keratinocytes caused by prolonged exposure to UV radiation o Treatment: Ablative and topical therapies (5-FU and imiquimod), protection from the sun
32
Cutaneous Squamous Cell Carcinoma
o Tumor of the epidermis o Types: In situ (Bowen disease) and invasive o Mutation of the TP53 gene and other oncogenic signals o Treatment: Cryotherapy, 5-FU, photodynamic therapy
33
Cutaneous Melanoma
Is a tumor of the skin originating from melanocytes ABCDE rule is used as a guide  Asymmetry  Border irregularity  Color variation  Diameter larger than 6 mm  Elevation that includes a raised appearance or rapid enlargement Treatment
34
Kaposi Sarcoma
- Vascular malignancy - Presentations  Drug-induced immunosuppression: After kidney transplantation, for example  Endemic form in equatorial Africa  Classic form, exhibited on the lower legs of older men  Epidemic and nonepidemic forms related to acquired immunodeficiency syndrome (AIDS) - Kaposi-associated herpes virus 8 (HHV-8) found in all forms
35
Treatment of Kaposi Sarcoma
- Incurable - Local lesions: Surgical excision - Multiple disseminated: Combination of immunomodulatory, cytotoxic, and antiviral drugs - Highly active antiretroviral therapy (HAART) for treating AIDS: Decreasing the incidence rate
36
Folliculitis
o Infection of hair follicles o Staphylococcus aureus: Common cause o Treatment: Soap and water and topical application of antibiotics
37
Furuncles
o Boils: Inflammation of the hair follicles o Develop from preceding folliculitis; spread through follicular wall into the surrounding dermis o S. aureus: Common causative organism
38
Carbuncles
- Collection of infected hair follicles - Erythematous, painful, swollen mass that drains through many openings - Development of abscesses - Clinical manifestations  Systemic symptoms that occur during early stages: Chills, fever, malaise
39
Paronychia
- Bacterial (acute or chronic) infection of the cuticle - Clinical manifestations: Painful; abscess may develop - Treatment  Hands: Kept dry  Abscesses: Incision and drainage  Severe bacterial cases: Systemic antibiotics
40
Onychomycosis
- Fungal or dermatophyte infection of the nail plate - Clinical manifestations: Turns yellow or white - Treatment  Débridement  Systemic antifungal therapy
41
The four phases of nociception
- Transduction - Transmission - Perception - Modulation
42
Heat loss - Radiation
o Heat loss through electromagnet waves (come from surfaces with temperatures higher than the surrounding air temperature)
43
Heat loss - Conduction
o Direct molecule to molecule transfer from one surface to another (warmer surface loses heat to the cooler surface)
44
Heat loss - Convection
o Transfer of heat through currents of gases or liquids (exchanging warmer air at the surface of the body with cooler air in the surrounding space)
45
Heat loss - Vasodilation
Diverting core-warmed blood to the surface of the body
46
Altered levels of arousal or altered levels of consciousness - Confusion
o Loss of the ability to think rapidly and clearly; impaired judgment and decision making
47
Altered levels of arousal or altered levels of consciousness - Disorientation
Beginning loss of consciousness; disorientation to time, followed by disorientation to place and impaired memory; recognition of self is lost last
48
Altered levels of arousal or altered levels of consciousness - Lethargy
Limited spontaneous movement or speech; easy arousal with normal speech or touch; may not be oriented to time, place, or person
49
Altered levels of arousal or altered levels of consciousness - Obtundation
Mild-to-moderate reduction in arousal (awakeness) with limited response to the environment; falls asleep unless verbally or tactilely stimulated; answers questions with minimum responses
50
Altered levels of arousal or altered levels of consciousness - Stupor
Condition of deep sleep or unresponsiveness; person may be aroused or caused to open eyes only by vigorous and repeated stimulation; response is often withdrawal or grabbing at stimulus
51
Altered levels of arousal or altered levels of consciousness - Coma
No verbal response to the external environment or to any stimuli; noxious stimuli such as deep pain or suctioning yields motor movement
52
Altered levels of arousal or altered levels of consciousness - Light coma
Associated with purposeful movement on stimulation
53
Altered levels of arousal or altered levels of consciousness - Deep coma
Associated with unresponsiveness or no response to any stimulus
54
Brain death criteria
Brain has no potential for recovery and can no longer maintain the body’s internal homeostasis State laws  Entire brain, brainstem, and cerebellum stops functioning   Brain is autolyzing (self-digesting) or has already autolyzed on postmortem examination
55
Cerebral death
o Death of the cerebral hemispheres is exclusive of the brainstem and cerebellum o Brainstem may continue to maintain internal homeostasis (normal respiratory and cardiovascular functions, temperature control, and gastrointestinal function)
56
Parkinson’s Disease
Severe degeneration of the basal ganglia (corpus striatum) involving the dopaminergic nigrostriatal pathway
57
Primary Parkinsonism
Onset after age 40 years old
58
Secondary Parkinsonism
* Caused by other neurodegenerative diseases and acquired disorders * Most common form is Drug-induced Parkinsonism
59
Clinical manifestations of Parkinson's
 Wide-eyed, unblinking, staring expression with immobile facial muscles  Slow gait  Short, shuffling steps
60
Treatment of Parkinson's
 Drug therapy: levodopa, anticholinergic drugs, antihistamines, amantadine  Occupational therapy, physical therapy, language, and swallowing therapy
61
Glasgow Coma Scale
o A way to assess the level of consciousness in a patient with acute brain injury
62
Scores within the Glasgow Coma Scale
Scores range from 3 to 15  Mild: GCS score of 13–15; is associated with mild concussion  Moderate: GCS score of 9–12; is associated with structural injury such as hemorrhage or contusion  Severe: GCS score of 3–8; is associated with cognitive and/or physical disability or death
63
Epidural (extradural) hematoma
Is caused most commonly by motor vehicle accidents (MVAs) but also occasionally by falls and sporting accidents Temporal fossa: is the most common site  Is caused by injury to the middle meningeal artery or vein
64
Clinical manifestations of Epidural (extradural) hematoma
 Include loss of consciousness at the time of injury, followed by a lucid period that lasts from a few hours to a few days, and increasingly severe headaches, vomiting, drowsiness, confusion, seizure, and hemiparesis
65
Treatment of Epidural (extradural) hematoma
Is a medical emergency; surgical evacuation of the hematoma
66
Acute Subdural Hemotoma
 Develops within hours  Is often located at the top of the skull  Expanding clots directly compress the brain
67
Subacute Subdural Hemotoma
 Develops after 48 hours to 2 weeks
68
Chronic Subdural Hemotoma
 Develops over weeks to months  Subdural space gradually fills with blood
69
Clinical manifestations of Acute Subdural Hemotoma
Begins with headache, drowsiness, restlessness or agitation, slowed cognition, and confusion
70
Treatment of Acute Subdural Hemotoma
Burr hole to remove the clot
71
Clinical manifestations of Chronic Subdural Hemotoma
Approximately 80% complain of chronic headaches and have tenderness at the site of injury
72
Treatment of Chronic Subdural Hemotoma
Craniotomy to evacuate the gelatinous blood Percutaneous drainage
73
Intracerebral hematoma
Hematoma acts as an expanding mass  Increased ICP and compression of brain tissues with resultant edema and ischemia Delayed: appears 3–10 days after injury
74
Clinical manifestations of Intracerebral hematoma
Decreasing level of consciousness
75
Treatment of Intracerebral hematoma
 Reducing ICP; allowing the hematoma to reabsorb slowly  Surgery
76
Diffuse axonal injury
Mechanisms  Rotational and twisting movements  Acceleration-deceleration forces Axonal damage  Shearing or stretching of nerve fibers
77
Categories of Diffuse Axonal Injury
- Mild concussion - classic concussion - mild TBI - moderate TBI - severe TBI
78
Types of strokes
Transient Ischemic Attack Thrombotic stroke Embolic stroke Hemorrhagic stroke
79
Transient Ischemic Attack
Neurologic deficits are not permanent Clinical Manifestations  Weakness, numbness, sudden confusion, loss of balance, loss of vision, or sudden severe headache
80
Thrombotic stroke
o Arterial occlusions are caused by thrombi formed in the arteries that supply the brain or in intracranial vessels o Is attributed to atherosclerosis and inflammatory disease processes
81
Embolic stroke
o Fragments break from a thrombus that is formed outside of the brain o A second stroke usually occurs
82
Hemorrhagic stroke
o Is spontaneous bleeding into the brain o Is also called spontaneous intracranial hemorrhage o Systolic and diastolic pressures have significantly increased over several years
83
Clinical manifestations of Hemorrhagic stroke
Focal neurologic deficits, altered consciousness, headache
84
Treament of Hemorrhagic stroke
 Needs to be initiated within 3–4 hours of symptom onset  Limit hematoma enlargement  Prevent or control seizures and cerebral edema
85
Myasthenia Gravis
Chronic autoimmune disease o Immunoglobulin G (IgG) antibody produced against acetylcholine receptors on the postsynaptic membrane Defect in nerve impulse transmission at the neuromuscular junction o Autoantibodies, complement deposits, and membrane attack complexes destroy the acetylcholine receptor (AChR) sites, causing decreased transmission of the nerve impulse
86
Clinical manifestations of Myasthenia Gravis
o Exertional fatigue and weakness that worsens with activity, improves with rest, and recurs with resumption of activity o Weakness and fatigue of muscles of the eyes and the throat, causing diplopia, difficulty chewing, talking, and swallowing
87
Myasthenic crisis
severe muscle weakening, leading to respiratory distress
88
Clinical manifestations of Cholinergic crisis
resembles myasthenic crisis but weakness occurs 30–60 minutes after taking anticholinergic medication
89
Treatment of Myasthenia crisis
Plasmapheresis
90
Treatment of Myasthenia Gravis - Cholinergic crisis
 Withhold anticholinergic drugs until blood toxic levels fall  Provide ventilatory support  Prevent respiratory complications
91
Treatment of Myasthenia Gravis
 Anticholinesterase drugs, corticosteroids, immunosuppressant drugs (Rituximab, a chimeric monoclonal antibody against the protein CD20, primarily found on B cells), azathioprine, cyclosporine, mycophenolate mofetil  Immunotherapy
92
Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH)
- Levels of antidiuretic hormone (ADH) are abnormally high - Ectopic secretion of ADH is the most common cause; is also common after surgery and some cancers - Water retention: action of ADH on renal collecting ducts increases their permeability to water, thus increasing water reabsorption by the kidneys - For diagnosis, normal renal, adrenal, and thyroid function must exist
93
Clinical Manifestations of Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH)
o Hyponatremia: sodium <135 mEq/L o Hypoosmolality: <280 mOsm/kg o Urine hyperosmolality: higher than serum osmolality o Hypervolemia o Weight gain o Serum sodium levels below 110–115 mEq/L: can cause severe and sometimes irreversible neurologic damage
94
Treatment of Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH)
o Correction of underlying causal problems o Emergency correction of severe hyponatremia by the administration of hypertonic saline o Vaptans o Most important: fluid restriction between 800 and 1000 mL/day o Resistant or chronic SIADH: demeclocycline
95
Diabetes Insipidus - Neurogenic
Insufficient amounts of ADH o Polyuria and polydipsia o Partial or total inability to concentrate the urine
96
Diabetes Insipidus - Nephrogenic
Insensitivity of the renal collecting tubules to ADH
97
Diabetes Insipidus - Dipsogenic
Excessive fluid intake, lowering plasma osmolarity to the point that it falls below the threshold for ADH secretion
98
Diabetes Insipidus
Is characterized by the inability of the kidney to increase permeability to water o Excretion of large volumes of dilute urine o Increase in plasma osmolality: 300 mOsm or more, depending on adequate water intake o Urine output: 8–12 L/day; normal output: 1–2 L/day
99
Clinical manifestations of Diabetes Insipidus
o Polyuria, nocturia, continual thirst o Low urine-specific gravity: <1.010 o Low urine osmolality (<200 mOsmL/kg) o Hypernatremia o Diuresis
100
Treatment of Diabetes Insipidus - Neurogenic
administration of the synthetic vasopressin analog desmopressin acetate (DDAVP)
101
Treatment of Diabetes Insipidus - Nephrogenic
treatment of any reversible underlying disorders, discontinuation of etiologic medications, and correction of associated electrolyte disorders; administration of thiazide diuretic agents
102
Treatment of Diabetes Insipidus - Dipsogenic
effective management of water ingestion
103
Clinical manifestations of Acromegaly
Connective tissue proliferation o Enlarged tongue, interstitial edema, increase in size and function of sebaceous and sweat glands, coarse skin and body hair Bony proliferation o Large joint arthropathy, kyphosis, enlargement of facial bones and hands and feet, protrusion of the lower jaw and forehead, need for increasingly larger sized shoes, hats, rings, and gloves Symptoms of diabetes o Polyuria and polydipsia Central nervous system (CNS) symptoms o Headache, seizure activity, visual disturbances, papilledema
104
Treatment of Acromegaly
o Primary treatment: transsphenoidal surgery or endonasal endoscopic surgery for the removal of the GH-secreting adenoma o Radiation therapy o Octreotide, octreotide long-acting, and lanreotide (somatostatin analogs) to lower GH levels o Cabergoline (dopaminergic agonists) to lower prolactin levels o Pegvisomant to block GH receptor
105
Graves Disease
o Hyperthyroid condition o Is an autoimmune disease; develops autoantibodies
106
Clinical manifestations of Graves Disease
 Ophthalmopathy * Exophthalmos: increased secretion of hyaluronic acid, orbital fat accumulation, inflammation, and edema of the orbital contents * Diplopia: double vision  Pretibial myxedema (Graves dermopathy): leg swelling
107
Treatment of Graves Disease
 Antithyroid drugs, radioactive iodine, or surgery  Does not reverse infiltrative ophthalmopathy or pretibial myxedema
108
Primary hypothyroidism
 Iodine deficiency (endemic goiter): most common worldwide  Autoimmune thyroiditis (Hashimoto disease): most common hypothyroidism in the United States
109
Congenital hypothyroidism
 Thyroid hormone deficiency present at birth  If not treated, cretinism develops  Neonatal screening to reduce incidents  Administration of T4
110
Thyroid carcinoma
 Most common endocrine malignancy from ionizing radiation  Changes in voice and swallowing and difficulty in breathing, related to a tumor growth impinging the trachea or esophagus  Some may have normal T3 and T4 levels
111
Clinical manifestations of hypothyroidism
 Low basal metabolic rate, cold intolerance, lethargy, tiredness, and slightly lowered basal body temperature; also possible diastolic hypertension  Myxedema  Nonpitting, boggy edema, especially around the eyes, hands, and feet; thickening of the tongue  Myxedema coma  Medical emergency, diminished level of consciousness; hypothermia without shivering, hypoventilation, hypotension, hypoglycemia, lactic acidosis, and coma
112
Treatment of hypothyroidism
 Levothyroxine (synthetic hormone)  Myxedema coma  Thyroid hormone, combined with circulatory and ventilatory support  Management of hyponatremia and hypothermia
113
Primary hyperparathyroidism
 Excess secretion of PTH from one or more parathyroid glands and hypercalcemia  80%–85% caused by parathyroid adenomas
114
Secondary hyperparathyroidism
 Increase in PTH, secondary to a chronic disease * Chronic renal failure * Dietary deficiency of vitamin D, calcium  Hypercalcemia does not occur
115
Tertiary hyperparathyroidism
 Excessive secretion of PTH and hypercalcemia from long-standing secondary hyperparathyroidism
116
Familial hypocalciuric hypercalcemia: benign autosomal dominant condition
inherited disorder that causes abnormally high levels of calcium in the blood (hypercalcemia) and low to moderate levels of calcium in urine (hypocalciuric)
117
Clinical manifestations of hypothyroidism
 Most asymptomatic  Hypercalcemia and hypophosphatemia, possible kidney stones from hypercalciuria, alkaline urine, pathologic fractures  Secondary: low serum calcium but elevated PTH
118
Treatment of hypothyroidism
Surgery, bisphosphonates, corticosteroids, and calcimimetics
119
Hypoparathyroidism
o Abnormally low PTH levels  Depressed serum calcium level  Increased serum phosphate level o Usual causes: parathyroid damage in thyroid surgery, autoimmunity, or genetic mechanisms o Pseudohypoparathyroidism: inherited condition
120
Clinical manifestations of hypoparathyroidism
 Hypocalcemia  Lowering of the threshold for nerve and muscle excitation  Muscle spasms; hyperreflexia; tonic-clonic convulsions; laryngeal spasms; death from asphyxiation  Chvostek and Trousseau signs  Phosphate retention
121
Treatment of hypoparathyroidism
 Calcium and vitamin D  Phosphate binders, if needed
122
Autoimmune Type I Diabetes
* Environmental and genetic factors are thought to trigger cell-mediated destruction of pancreatic beta cells (type 1A) * Autoantibody, T-cell, and macrophage destruction of pancreatic beta cells occur with a loss of insulin production and a relative excess of glucagon
123
Non-immune Type I Diabetes
Occurs secondary to other diseases, such as pancreatitis, or secondary to a more fulminant disorder termed idiopathic diabetes (type 1B)
124
Clinical Manifestations of Type I Diabetes
 Long preclinical period with gradual beta-cell destruction, leading to insulin deficiency and hyperglycemia  Loss of function of the insulin-secreting beta cells in the islet of Langerhans occurs before hyperglycemia develops  Polydipsia, polyuria, polyphagia, weight loss, and fatigue
125
Treatment of Type I Diabetes
 Combination of insulin, meal planning, exercise, and self-monitoring of blood glucose  Transplant: islet cells and the whole pancreas
126
Type II Diabetes
o Is more common than type 1 diabetes mellitus o Genetic, epigenetic, and environmental interactions: must be genetically predisposed o Insulin resistance and decreased insulin secretion by beta cells: are major mechanisms
127
Insulin resistance in Type II DIabetes
 Response of insulin-sensitive tissues (especially liver, muscle, and adipose tissue) to insulin is suboptimal  Obesity makes one prone to insulin resistance
128
Beta cell dysfunction in Type II Diabetes
 Beta cell mass is decreased  Inflammation and changes occur in adipokines
129
Glucagon in Type II Diabetes
 Pancreatic alpha cells are less responsive to glucose inhibition; hyperglycemia—abnormally high levels of glucagon increase hepatic production of glucose
130
Clinical manifestations of Type II Diabetes
 Fatigue, pruritus, recurrent infections, visual changes, or symptoms of neuropathy (paresthesia or weakness)
131
Addison Disease
o Primary adrenal insufficiency, hypocortisolism o Rare, autoimmune mechanisms o Inadequate corticosteroid and mineralocorticoid synthesis; elevated ACTH
132
Clinical manifestations of Addison Disease
 Hypocortisolism and hypoaldosteronism  Weakness, hyperpigmentation, vitiligo
133
Treatment of Addison Disease
 Lifetime glucocorticoid and mineralocorticoid replacement therapy; 150 mEq sodium per day
134
Cushing disease
 Overproduction of pituitary ACTH by a pituitary adenoma  Lose diurnal and circadian patterns of ACTH and cortisol secretion  Lack of ability to increase ACTH and cortisol in response to stressors
135
Clinical Manifestations of Cushing's
 Weight gain of adipose tissue in the trunk, facial, and cervical areas  Is described as “truncal [central] obesity,” “moon face,” and “buffalo hump”  Sodium and water retention, glucose intolerance, protein wasting  Renal stones  Purple striae  Bronze or brownish hyperpigmentation of the skin
136
Treatment of Cushing's
Medication, radiation, surgery
137
Leukocyte
o AKA white blood cell (WBC) o Defense mechanisms
138
Lymphocyte
Humoral and cell mediated immunity
139
Monocyte and macrophage
Phagocytosis; mononuclear phagocyte system
140
Neutrophil
Phagocytosis; particularly during early phase of inflammation, bactericidal
141
Basophil
Inflammatory response, often present in allergic reactions
142
Eosinophil
Anti-parasitic and antibacterial
143
Pernicious anemia
Is the most common macrocytic anemia Is caused by a vitamin B12 deficiency Lacks intrinsic factor from the gastric parietal cells  Required for vitamin B12 absorption May be congenital or autoimmune disorder  Autoantibodies against intrinsic factor
144
Conditions that increase risk of pernicious anemia
 Genetics  Endocrine disorders  Gastrectomy, ileal resection, tapeworms, demand of vitamin B12
145
Clinical manifestations of pernicious anemia
 Weakness, fatigue  Paresthesias of the feet and fingers, difficulty walking  Loss of appetite, abdominal pains, weight loss  Sore tongue that is smooth and beefy red, secondary to atrophic glossitis  “Lemon yellow” (sallow) skin as a result of a combination of pallor and icterus  Hepatomegaly, splenomegaly  Neurologic symptoms from nerve demyelination • Not reversible, even with treatment  Is often unrecognizable in older adults because of its subtle, slow onset and presentation
146
Treatment of pernicious anemia
 Weekly/monthly injections or high oral doses of vitamin B12 are administered  If left untreated, death will result
147
Iron deficiency anemia
o Most common type of anemia worldwide o Highest risk: toddlers, adolescent girls, women of childbearing age, those living in poverty, infants consuming cow’s milk, older adults on restrictive diets, teenagers on junk food diets
148
Causes of iron deficiency anemia
 Dietary lack and eating disorders  Impaired absorption  Increased requirement  Chronic blood loss  Medications (that cause GI bleeding)  Some surgeries
149
Clinical manifestations of iron deficiency anemia
 Fatigue, weakness, shortness of breath  Pale earlobes, palms and conjunctivae  Brittle, thin, coarsely ridged, and spoon-shaped (concave or koilonychia) nails  Burning mouth  Angular stomatitis: dryness and soreness in the corners of the mouth  Become symptomatic: when hemoglobin (Hgb) 7–8 g/dL
150
Treatment of iron deficiency anemia
 Identify and eliminate sources of blood loss  Iron replacement therapy: PO, IM, IV  Sodium ferric gluconate complex in sucrose (Ferrlecit) and iron sucrose injection (Venofer)  Duration of therapy: usually 6–12 months after the bleeding has stopped but may continue for as long as 24 months
151
Aplastic anemia
Most aplastic anemias are autoimmune disorders; some are due to chemicals, drugs, physical agents, unpredictable exposures; inherited or idiosyncratic Pathophysiology  Hypocellular bone marrow that has been replaced with fat
152
Pancytopenia
Reduction or absence of all three types of blood cells
153
Fanconi anemia
 Rare genetic anemia from defects in DNA repair
154
Clinical manifestations of aplastic anemia
 Hypoxemia, pallor (occasionally with a brownish pigmentation of the skin)  Weakness along with fever and dyspnea with rapidly developing signs of hemorrhaging if platelets are affected
155
Treatment of aplastic anemia
 Bone marrow transplantation Peripheral blood stem cell transplantation * May receive radiation or chemotherapy before procedure Immunosuppression * Antithymocyte globulin with cyclosporin * Corticosteroidal medications Identification of high-risk individuals If not treated or identified, death occurs
156
Hemolytic anemia
o Accelerated destruction of RBCs o Congenital versus acquired o Intravascular versus extravascular hemolysis o Paroxysmal nocturnal hemoglobinuria  Deficiency in CD55 and CD59: cause complement-mediated intravascular lysis and release of hemoglobin  Anemia, hemoglobinuria, severe fatigue, abdominal pain, and thrombosis
157
Autoimmune hemolytic anemia
 Autoantibodies against antigens normally on the surface of erythrocytes  Warm reactive antibody type  Cold agglutinin type  Cold hemolysin type (paroxysmal cold hemoglobinuria)  Based on the optimal temperature at which the antibody binds to the erythrocytes
158
Warm autoimmune hemolytic anemia
Uncommon but most common form of AIHA
159
Cold agglutinin autoimmune hemolytic anemia
IgM antibodies
160
Drug-induced hemolytic anemia
 Form of immune hemolytic anemia that is usually the result of an allergic reaction against foreign antigens  Called the hapten model  Caused by penicillin, cephalosporins (more than 90%), hydrocortisone
161
Clinical manifestations of hemolytic anemia
 May be asymptomatic  Jaundice (icterus)  Aplastic crisis  Splenomegaly
162
Treatment of hemolytic anemia
 Acquired: removal of the cause or treatment of the underlying disorder  First line: corticosteroids  Second line: splenectomy and rituximab (monoclonal antibody)  Paroxysmal nocturnal hemoglobinuria: eculizumab
163
Disseminated Intravascular Coagulation (DIC)
o Complex, acquired disorder: clotting and hemorrhage simultaneously occur o Cause: variety of clinical conditions that release tissue factor o Characterized by a cycle of intravascular clotting, followed by active bleeding
164
Clinical manifestations of Disseminated Intravascular Coagulation (DIC)
Wide variability  Bleeding from venipuncture sites  Bleeding from arterial lines  Bleeding from surgical wounds  Purpura, petechiae, and hematomas  Symmetric cyanosis of the fingers and toes
165
Treatment of Disseminated Intravascular Coagulation (DIC)
 Eliminate underlying pathology  Control thrombosis  Maintain organ function  Administer replacement therapy  Replace anticoagulants
166
Acute lymphocytic leukemia (ALL)
o Greater than 30% lymphoblasts in bone marrow or blood o Genetic anomaly: Philadelphia chromosome
167
Acute myelogenous leukemia (AML)
Most common adult leukemia (older than 50 years) Clinical manifestations  Fatigue caused by anemia  Bleeding resulting from thrombocytopenia (reduced numbers of circulating platelets)  Fever caused by infection  Anorexia, weight loss, diminished sensitivity to sour and sweet tastes, muscle atrophy, and difficulty swallowing  Central nervous system (CNS) involvement
168
Hodkins lymphoma
Reed-Sternberg cells in the lymph nodes o Are necessary for the diagnosis but not specific to Hodgkin lymphoma o Are derived from malignant B cells that usually become binucleate o Release cytokines
169
Classic Hodgkin lymphoma
derived from B cell in the germinal center that has not undergone successful immunoglobulin gene rearrangement and would normally be induced to undergo apoptosis
170
Nodular lymphocyte-predominant Hodgkin
presents with earlier stage disease, longer survival, and fewer treatment failures [10% have a tendency to histologically transform into diffuse large B-cell lymphoma]
171
Clinical manifestations of Hodgkin Lymphoma
o Enlarged painless neck lymph nodes o Lymphadenopathy, causing pressure or obstruction o Mediastinal mass o Fever, weight loss, night sweats, pruritus, fatigue
172
Treatment of Hodgkin Lymphoma
o Approximate cure rate: 75% o Combined treatment with radiation therapy and chemotherapy o High-dose chemotherapy with bone marrow or stem cell transplantation o Monoclonal antibodies o Nonmyeloablative allogeneic stem cell transplantation
173
Non-Hodkins lymphoma
- WHO/REAL scheme now calls this "B cell neoplasms" and includes T-cell and natural killer (NK) neoplasms - Is linked to chromosome translocations - Clonal expansion of B cells (85%–90%), T cells, and/or NK cells occurs - Changes in proto-oncogenes and tumor-suppressor genes contribute to cell immortality and thus an increase in malignant cells
174
Clinical manifestations of Non-Hodgkins Lymphoma
o Localized or generalized painless lymphadenopathy o Nodal enlargement and transformation over months or years o Retroperitoneal and abdominal masses with symptoms of abdominal fullness and back pain o Ascites (fluid in the peritoneal cavity) and leg swelling
175
Treatment of Non-Hodgkins Lymphoma
o Survival: extended periods but less than the survival rate for Hodgkin lymphoma o Dependent on the type (B cell or T cell), tumor stage, histologic status (low, intermediate, high grade), symptoms, age, and any comorbidities o Chemotherapy or radiation o Combination of chemotherapy and radiation o Monoclonal antibody: rituximab o Radioimmunotherapy: combination of radiation therapy with monoclonal antibody therapy